Johnson & Johnson (NYSE:JNJ) Shares Purchased by McAdam LLC

McAdam LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,334 shares of the company’s stock after acquiring an additional 168 shares during the period. McAdam LLC’s holdings in Johnson & Johnson were worth $926,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. LRI Investments LLC boosted its holdings in Johnson & Johnson by 24.1% in the 2nd quarter. LRI Investments LLC now owns 12,271 shares of the company’s stock worth $1,794,000 after acquiring an additional 2,381 shares during the period. EWA LLC boosted its stake in shares of Johnson & Johnson by 20.7% in the second quarter. EWA LLC now owns 1,957 shares of the company’s stock valued at $298,000 after purchasing an additional 335 shares during the period. Advisory Resource Group grew its holdings in Johnson & Johnson by 20.2% during the 2nd quarter. Advisory Resource Group now owns 30,096 shares of the company’s stock valued at $4,399,000 after purchasing an additional 5,060 shares in the last quarter. TrueWealth Advisors LLC increased its stake in Johnson & Johnson by 21.5% during the 2nd quarter. TrueWealth Advisors LLC now owns 5,446 shares of the company’s stock worth $796,000 after buying an additional 964 shares during the period. Finally, Keynote Financial Services LLC lifted its holdings in Johnson & Johnson by 7.2% in the 2nd quarter. Keynote Financial Services LLC now owns 10,924 shares of the company’s stock worth $1,597,000 after buying an additional 731 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 1.1 %

Johnson & Johnson stock opened at $164.13 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $143.13 and a one year high of $167.78. The company has a 50-day simple moving average of $153.92 and a 200-day simple moving average of $153.24. The firm has a market capitalization of $395.01 billion, a P/E ratio of 10.23, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion during the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.80 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.02%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a research note on Tuesday, July 30th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 5th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.21.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.